Free Trial
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$43.24 -3.49 (-7.47%)
Closing price 04:00 PM Eastern
Extended Trading
$43.21 -0.03 (-0.07%)
As of 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Key Stats

Today's Range
$42.98
$46.16
50-Day Range
$45.19
$57.17
52-Week Range
$24.00
$58.38
Volume
1.31 million shs
Average Volume
797,366 shs
Market Capitalization
$3.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.77
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Remove Ads

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 221st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is -7.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.90% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.90% of the float of PTC Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    2 people have searched for PTCT on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,799,047.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 at the beginning of 2025. Since then, PTCT stock has decreased by 4.2% and is now trading at $43.24.
View the best growth stocks for 2025 here
.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.39) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.15. The biopharmaceutical company had revenue of $196.79 million for the quarter, compared to analysts' expectations of $173.51 million.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
11/07/2024
Today
4/04/2025
Next Earnings (Estimated)
4/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.77
High Stock Price Target
$113.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+47.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-626,600,000.00
Pretax Margin
-47.24%

Debt

Sales & Book Value

Annual Sales
$806.78 million
Cash Flow
$2.08 per share
Price / Cash Flow
20.80
Book Value
($10.85) per share
Price / Book
-3.99

Miscellaneous

Free Float
72,883,000
Market Cap
$3.41 billion
Optionable
Optionable
Beta
0.58

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners